Key Takeaway: Vir Biotechnology, Inc. will host a conference call on February 23, 2026, to discuss its financial results for the fourth quarter and full year ending December 31, 2025. The call aims to provide a corporate update and is accessible via the company's website. Vir Biotechnology focuses on developing treatments for infectious diseases and cancer.
Price reaction · baseline $7.28 (2026-02-09 close) · hit pre-market · clean, no other VIR news in the window
day 0 close · peak
+3.2%
Market Sentiment Analysis
POSITIVE FACTORS
Vir Biotechnology is actively engaging with investors through a conference call.
The company is focused on developing innovative treatments for serious diseases.
The upcoming financial results may indicate strong performance and growth.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
14%
average across 4 past catalysts
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis
Full Press Release Details
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate update and discuss its financial results for the fourth quarter and full year ended December 31, 2025. The conference call may be accessed on theEvents & Presentationspage of the Vir Biotechnology website.
About Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN®dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Vir Biotechnology retains exclusive rights to the PRO-XTEN®masking platform for oncology and infectious disease. PRO-XTEN®is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
Frequently Asked Questions
When will Vir Biotechnology hold its conference call?
Vir Biotechnology will hold its conference call on February 23, 2026.
What will be discussed during the conference call?
The conference call will cover the financial results for Q4 and the full year of 2025.
How can I access the conference call?
The conference call can be accessed on the Events & Presentations page of Vir Biotechnology's website.
What is the focus of Vir Biotechnology?
Vir Biotechnology focuses on developing medicines for serious infectious diseases and cancer.